

This is a repository copy of *Programmed death 1 expressing regulatory T cells in vitiligo*.

White Rose Research Online URL for this paper: http://eprints.whiterose.ac.uk/85671/

Article:

Kemp, E.H. (2015) Programmed death 1 expressing regulatory T cells in vitiligo. British Journal of Dermatology, 172 (4). 847 - 848. ISSN 1365-2133

https://doi.org/10.1111/bjd.13595

Reuse

Unless indicated otherwise, fulltext items are protected by copyright with all rights reserved. The copyright exception in section 29 of the Copyright, Designs and Patents Act 1988 allows the making of a single copy solely for the purpose of non-commercial research or private study within the limits of fair dealing. The publisher or other rights-holder may allow further reproduction and re-use of this version - refer to the White Rose Research Online record for this item. Where records identify the publisher as the copyright holder, users can verify any specific terms of use on the publisher's website.

Takedown

If you consider content in White Rose Research Online to be in breach of UK law, please notify us by emailing eprints@whiterose.ac.uk including the URL of the record and the reason for the withdrawal request.



eprints@whiterose.ac.uk https://eprints.whiterose.ac.uk/

Commentary – Programmed death (PD) 1 expressing regulatory T cells in vitiligo

Vitiligo is a common depigmenting skin disease with a prevalence of 1-2%.¹ The exact aetiology and detailed pathogenesis of vitiligo is not fully understood, but destructive CD8⁺ T cell responses against melanocytes are strongly implicated in the development of the disease.²⁻³ Regulatory T cells (Tregs) are a subset of CD4+ lymphocytes that play a key role in maintaining peripheral tolerance *in vivo* through the active suppression of self-reactive T cell activation and expansion.⁴ Several studies have reported dysregulation of Tregs in vitiligo patients,⁵⁻⁶ and repigmentation in a mouse model of spontaneous epidermal depigmentation was found to be accompanied by an increased Treg cell infiltration, suggesting their importance in preventing an ongoing immune response against melanocytes.⁷

In this issue of *BJD*, the findings of Tembhre *et al*⁸ support a role for Tregs in vitiligo pathogenesis. They report a decrease in the frequency of Treg cells and a reduction in the expression of Treg cell-associated molecules such as TGF-β, FOXP3 and chemokine receptor CCL21 in the peripheral blood and the lesional skin of vitiligo patients. Tregs mediate their suppressive function through the programmed death 1 (PD1)/PD1-ligand pathway.⁹ PD1 is an inhibitory cell surface molecule that inhibits activation of autoreactive T and B cells, suppresses their proliferation, and induces apoptosis on interaction with PD1-ligand on Treg cells.⁹ Blocking PD1-ligand *in vitro* causes the expansion of Tregs suggesting the mechanism by which Treg function is contra-regulated on PD1/PD1-ligand engagement.¹⁰ In the current report⁸, the authors observed an increase in the frequency of peripheral PD1+Tregs and CD3+CD4+PD1+ T cells in vitiligo patients compared to healthy controls. They hypothesise

that increased expression of PD1 on Treg cells may be acted upon by autoreactive T cells expressing PD1-ligand leading eventually to the apoptosis of Tregs and their consequent deficiency in vitiligo patients. However, their hypothesis requires much further investigation to provide evidence to support it as a mechanism for Treg cell dysfunction in vitiligo.

Conflicts of interest

None declared

DR. E. HELEN KEMP

Department of Human Metabolism

University of Sheffield

Sheffield S10 2RX

U.K.

Email – e.h.kemp@sheffield.ac.uk

References

- Alikhan A, Felsten LM, Daly M, Petronic-Rosic V. Vitiligo: a comprehensive overview Part I. Introduction, epidemiology, quality of life, diagnosis, differential diagnosis, associations, histopathology, etiology, and work-up. J Am Acad Dermatol 2011; 65:473-91.
- 2 Mosenson JA, Zloza A, Klarquist J *et al*. HSP70i is a critical component of the immune response leading to vitiligo. *Pigment Cell Melanoma Res* 2012; **25**:88-98.
- 3 van den Boorn JG, Konijnenberg D, Dellemijn TA *et al.* Autoimmune destruction of skin melanocytes by perilesional T cells from vitiligo patients. *J Invest Dermatol* 2009;
 129:2220-32.
- 4 Levings M, Sangregorio R, Roncarolo M. Human CD25(+)CD4(+) T regulatory cells suppress naive and memory T cell proliferation and can be expanded *in vitro* without loss of function. *J Exp Med* 2001; **193**:1295-302.
- 5 Dwivedi M, Laddha NC, Arora P *et al.* Decreased regulatory T-cells and CD4(+) /CD8(+) ratio correlate with disease onset and progression in patients with generalized vitiligo. *Pigment Cell Melanoma Res* 2013; **26**:586-91.
- 6 Klarquist J, Denman CJ, Hernandez C *et al*. Reduced skin homing by functional Treg in vitiligo. *Pigment Cell Melanoma Res* 2010; **23**:276-86.
- 7 Eby JM, Kang HK, Klarquist J *et al*. Immune responses in a mouse model of vitiligo with spontaneous epidermal de- and repigmentation. *Pigment Cell Melanoma Res* 2014; **27**:1075-85.
- 8 Tembhre MK, Parihar AS, Sharma VK *et al*. Alteration in regulatory T cells and programmed death (PD)1 expressing regulatory T cells in active generalized vitiligo and their clinical correlation *Br J Dermatol*; in press.

- 9 Gotot J, Gottschalk C, Leopold S *et al*. Regulatory T cells use programmed death 1 ligands to directly suppress autoreactive B cells *in vivo*. *Proc Natl Acad Sci USA* 2012;
 109:10468-73.
- 10 Franceschini D, Paroli M, Francavilla V *et al*. PD-L1 negatively regulates CD4+CD25+ Foxp3+ Tregs by limiting STAT-5 phosphorylation in patients chronically infected with HCV. *J Clin Invest* 2009; **119**:551-64.